CMAB Overview
- Year Founded
-
2017
- Status
-
Acquired/Merged
- Employees
-
250
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$24.4M
CMAB General Information
Description
Developer of cell line development research, aseptic drugs and GMP manufacturing. The company provides various antibodies and biologics such as aseptic drugs and GMP (guanosine monophosphate) for clients in China and across the globe through, enabling its clients to receive various pre-clinical and early-stage clinical products from them.
Contact Information
Website
www.cmabbio.comCorporate Office
- Building C37
- No. 188 Dongping Street, Suzhou Industrial Park
- Suzhou, Jiangsu 215123
- China
Corporate Office
- Building C37
- No. 188 Dongping Street, Suzhou Industrial Park
- Suzhou, Jiangsu 215123
- China
CMAB Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 07-May-2021 | $24.4M | Completed | Generating Revenue | ||
| 3. Early Stage VC (Series B1) | 02-Feb-2019 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series B) | 02-Apr-2018 | $34M | $72M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 02-Jan-2018 | $38M | $38M | Completed | Generating Revenue |
CMAB Comparisons
Industry
Financing
Details
CMAB Competitors (2)
One of CMAB’s 2 competitors is Solvias, a Private Equity-Backed company based in Kaiseraugst, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Solvias | Private Equity-Backed | Kaiseraugst, Switzerland | ||||
| Celonic | Corporate Backed or Acquired | Basel, Switzerland |
CMAB Signals
CMAB Former Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| CBC Group (Singapore) | PE/Buyout | Minority | ||
| CDBI Partners | Venture Capital | Minority | ||
| Cormorant Asset Management | PE/Buyout | Minority | ||
| Hangzhou Tigermed Consulting Company | Corporation | Minority | ||
| I-Bridge Capital | Venture Capital | Minority |
CMAB FAQs
-
When was CMAB founded?
CMAB was founded in 2017.
-
Where is CMAB headquartered?
CMAB is headquartered in Suzhou, China.
-
What is the size of CMAB?
CMAB has 250 total employees.
-
What industry is CMAB in?
CMAB’s primary industry is Other Pharmaceuticals and Biotechnology.
-
Is CMAB a private or public company?
CMAB is a Private company.
-
What is the current valuation of CMAB?
The current valuation of CMAB is .
-
What is CMAB’s current revenue?
The current revenue for CMAB is .
-
How much funding has CMAB raised over time?
CMAB has raised $72M.
-
Who are CMAB’s investors?
CBC Group (Singapore), CDBI Partners, Cormorant Asset Management, Hangzhou Tigermed Consulting Company, and I-Bridge Capital are 5 of 8 investors who have invested in CMAB.
-
Who are CMAB’s competitors?
-
When was CMAB acquired?
CMAB was acquired on 07-May-2021.
-
Who acquired CMAB?
CMAB was acquired by WuXi Biologics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process